ss-lup-332 FAQ

Restrict caffeine intake to morning hours only. Consumption after 2:00 PM will overlap with evening dosing windows and introduce the same confounding effects. ERRγ agonism doesn't follow a strict circadian pattern the way cortisol or growth hormone does, so evening dosing is methodologically sound as long as caffeine intake is confined to the first half of the day. This allows sufficient washout time (eight-plus hours) before the peptide is administered and measurements are taken.

Verify storage and reconstitution protocol first. Most non-responders trace back to degraded compound. If storage is confirmed correct, check baseline testosterone levels and AMPK-γ2 expression. Approximately 8% of males carry polymorphisms in the PRKAG2 gene that reduce allosteric activation, requiring 30–40% higher doses to achieve equivalent effects.

Sequence the protocol so ethanol exposure occurs at least 72 hours after the final SS-LUP-332 dose. Administer the peptide during the baseline metabolic assessment phase, allow full clearance (plasma half-life is 4–6 hours, but mitochondrial transcriptional effects persist 24–36 hours), then introduce the ethanol challenge. Reverse sequencing. Alcohol first, peptide second. Requires a minimum 48-hour gap to allow ERRα receptor recovery before peptide administration.

Expected. Mitochondrial expansion increases intracellular water and glycogen content in skeletal muscle by 0.3–0.7 kg in most individuals. This is not fat gain. It's infrastructure development. Fat oxidation is accelerating even as scale weight rises slightly. Body composition analysis (DEXA, bioimpedance) would show stable or slightly reduced fat mass alongside increased lean mass hydration. Judge progress by measurements, performance, and how clothes fit. Not scale weight alone in week one.

ERRα shares structural homology with other nuclear receptors—particularly ERRβ and ERRγ—and high doses of SS-LUP-332 may produce low-level cross-reactivity. Monitor liver function (ALT, AST) and kidney function (creatinine, BUN) weekly during extended studies (≥8 weeks). Histological examination of liver, kidney, and heart tissue at study termination is standard practice. In published studies, no adverse histological changes were observed at doses up to 50 mg/kg/day for 28 days, but longer durations (12+ weeks) have not been systematically evaluated. If toxicity appears, reduce dose by 30–50% and extend treatment duration to achieve target metabolic endpoints—lower doses administered longer often produce equivalent metabolic effects with reduced risk.

If your calculated injection volume falls below 0.1mL, increase reconstitution volume to dilute the peptide and raise per-dose volume into the measurable range. For example, if a 5mg vial reconstituted in 2mL yields 2.5mg/mL and your dose is 0.25mg (requiring 0.1mL injection), reconstitute in 2.5mL instead—concentration drops to 2mg/mL and your 0.25mg dose now requires 0.125mL, which is easier to measure reliably with a 1mL insulin syringe. This adjustment slightly increases the risk of dilution-related potency decline over the 28-day window, but measurement error at the dosing stage is a far greater threat to study validity than modest concentration reduction.

Preclinical evidence suggests yes, but no human data exists to confirm dosing, safety, or magnitude of effect. In rodent hindlimb suspension models. The closest analog to post-surgical immobilization. SLU-PP-332 reduced soleus muscle atrophy from 28% (vehicle) to 11% (treated) over 14 days. The protective effect required continuous dosing throughout the immobilization period and did not persist after cessation. If this translates to humans, a patient on bed rest for four weeks post-orthopedic surgery might retain 60–70% more lean mass than expected, preserving functional capacity for rehabilitation. The unknowns: oral bioavailability in humans, required dose, and whether the metabolic shift increases risk of hypoglycemia or electrolyte disturbances during recovery.

Dose-response variability, treatment duration, and baseline metabolic state all influence outcome magnitude. Published studies used sedentary mice with normal metabolic function—animals with pre-existing mitochondrial dysfunction (e.g., high-fat diet-induced obesity models) may require longer treatment durations or higher doses to achieve comparable effects. Treadmill exhaustion protocols must be standardized: speed, incline, and test termination criteria significantly affect measured endurance. Studies using incremental speed protocols (starting at 10 m/min, increasing 2 m/min every 2 minutes) consistently produce larger effect sizes than constant-speed protocols. Environmental factors—temperature, humidity, time of day—also introduce variability; conduct all endurance tests at the same time of day to control for circadian influences on performance.

Refuse delivery if the package exterior feels warm (above room temperature) or if ice packs inside have completely melted into liquid. Contact Real Peptides immediately with photos of the packaging condition and tracking number. A replacement shipment dispatches within 24 hours at no cost. Even if the vial appears intact, peptide exposed to temperatures above 8°C for unknown duration should not be used for critical research applications. Temperature logger data (if included) provides definitive evidence: excursions above 8°C lasting more than two hours warrant replacement regardless of visual appearance.

Remove GLP-1 agonists and replace with MOTS-C 10mg daily to shift focus from caloric deficit to mitochondrial function optimization. Endurance performance requires adequate glycogen stores and carbohydrate availability. GLP-1 agonists suppress appetite to the point where carbohydrate intake often drops below 3g/kg, impairing high-intensity performance. Keep SS-LUP-332 and NAD+ as the mitochondrial foundation, add MOTS-C for glucose metabolism and insulin sensitivity, and adjust macros to 50–60% carbohydrate (5–7g/kg on training days). Replace fasted morning cardio with glycogen-depleted Zone 2 sessions (low-carb day + morning training before first meal) to maximize fat adaptation while maintaining glycolytic capacity through high-carb/high-intensity days.

Compare reconstitution concentration first—bitterness scales predictably with mg/mL, so a 5mg/mL solution will taste noticeably sharper than a 2mg/mL preparation even from the same batch. If concentration is identical to previous preparations, check your reconstitution medium: switching from bacteriostatic water to saline or PBS amplifies bitterness due to added salts. If both variables are controlled and bitterness remains elevated, request a Certificate of Analysis (CoA) from your supplier to verify purity—formulations below 95% purity often contain residual synthesis byproducts that contribute additional bitter compounds beyond the peptide itself. Elevated bitterness isn't necessarily a safety issue, but it does signal formulation variance that should be documented before proceeding with research protocols requiring cross-batch consistency.

AMPK is already activated by energy deficit. Adding an exogenous AMPK activator may produce diminishing returns or no additive effect. Female rodent models subjected to 30% caloric restriction showed no further increase in skeletal muscle fatty acid oxidation when SS-LUP-332 was added, suggesting the endogenous AMPK activation from fasting saturates the pathway. The compound may hold greater research value in eucaloric or hypercaloric states where AMPK remains inactive despite excess substrate availability, particularly in insulin-resistant populations like those with PCOS.

SS-LUP-332 is a systemic agonist. It activates ERRα/γ wherever the receptors are expressed. For tissue-specific effects, researchers use Cre-lox conditional knockout models to delete ERR subtypes in non-target tissues, leaving only the tissue of interest capable of responding to SS-LUP-332. Alternatively, tissue-selective delivery via adeno-associated virus (AAV) vectors can drive localized ERR overexpression, creating tissue-specific hyperresponsiveness to pharmacological agonism. A third approach uses organ-restricted dosing: intraperitoneal injection delivers higher hepatic exposure than subcutaneous administration, while intramuscular injection creates local concentration gradients. Each method introduces confounds. Choose based on whether the research question prioritizes spatial resolution or systemic integration.

Choose injectable SS-LUP-332. Near-complete bioavailability (95–100%) produces predictable, reproducible plasma levels with minimal inter-subject variability. Oral bioavailability is influenced by gastric pH, food intake, intestinal transit time, and individual differences in hepatic metabolism. All of which introduce variability that can obscure treatment effects in smaller sample sizes.

Do not attempt to reconstitute or use peptide from damaged vials. Hairline cracks in glass compromise sterility even if the lyophilised powder looks intact. Bacterial contamination risk outweighs any research value. Photograph the damage immediately, document the tracking number and delivery condition, and contact Real Peptides for replacement. Vial damage most commonly occurs from freeze-shock during winter shipping or rough handling during customs inspection. Both are covered under shipping guarantee policies.

Cease SS-LUP-332 immediately and implement lactic acidosis monitoring protocol: venous blood gas with lactate measurement every 8 hours for 48 hours. If lactate remains below 2.0 mmol/L and the subject is asymptomatic, discontinue metformin and observe for 14-day washout before considering SS-LUP-332 re-initiation at 50% standard dose with weekly lactate monitoring. If lactate exceeds 4.0 mmol/L or the subject develops nausea, muscle cramping, or hyperventilation (classic lactic acidosis presentation), initiate emergency medical evaluation. Lactic acidosis from dual AMPK activation can progress to cardiovascular collapse within 6–12 hours. This scenario represents protocol violation requiring incident reporting to the institutional review board and review of screening procedures to prevent recurrence.

Start with Tesofensine 0.25mg daily and monitor heart rate and blood pressure for 2 weeks before escalating dose. Tesofensine increases norepinephrine, serotonin, and dopamine by inhibiting reuptake. The norepinephrine component raises heart rate 5–10 bpm and systolic BP 5–8 mmHg on average. If baseline BP is above 140/90 or resting HR above 80 bpm, thermogenic compounds are contraindicated. Alternatives include low-dose T3 (liothyronine) at 12.5–25mcg daily, which increases metabolic rate by upregulating mitochondrial uncoupling proteins, though thyroid supplementation requires more careful monitoring and post-cycle recovery. Combining Tesofensine with GLP-1 agonists is well-tolerated in clinical settings. Both were studied together in obesity trials without significant adverse event overlap.

Source it only from registered 503B facilities or suppliers with verified chain-of-custody documentation and third-party purity testing. Peptides entering research channels before formal approval often lack standardized synthesis protocols, leading to batch-to-batch variability in purity and potency. Verify the peptide sequence via mass spectrometry and request certificates of analysis (CoA) showing ≥98% purity with endotoxin levels below 1 EU/mg. Contamination at this stage compromises study reproducibility and introduces confounding variables that invalidate results.

Assume 10–15% degradation has occurred through oxidation and residual moisture hydrolysis. Reconstitute normally, but reduce expected potency by 15% when calculating dosing. The peptide will dissolve normally. Degradation at this level doesn't affect solubility. But efficacy is compromised. If the exposure exceeded 72 hours at 25°C, aggregate formation becomes likely, visible as cloudiness after reconstitution. Discard any reconstituted solution with visible particulates or persistent cloudiness.

A 12-hour room temperature exposure degrades approximately 25% of peptide bonds through accelerated hydrolysis. Use the solution immediately if research protocols allow reduced potency, or discard it if precise dosing is required. Do not return the vial to refrigeration and assume normal shelf life. The damage is done, and further refrigeration only slows additional degradation. Peptides like Ipamorelin or BPC 157 Peptide follow identical kinetics: aqueous solutions at room temperature degrade four times faster than refrigerated solutions.